Biomarin Pharmaceutical Stock News

NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the Class Period), of the important December 22, 2021 lead plaintiff deadline .

Raymond James Trust N.A. lifted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 6.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,657 shares of the biotechnology companys stock after acquiring an additional 236 shares during the period. Raymond James Trust N.A.s holdings []

Nisa Investment Advisors LLC trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 1.0% in the 3rd quarter, Holdings Channel reports. The firm owned 20,717 shares of the biotechnology companys stock after selling 213 shares during the quarter. Nisa Investment Advisors LLCs holdings in BioMarin Pharmaceutical were worth $1,601,000 at the end of the most []

NEW YORK , Dec. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) between January 13, 2020 and September 3, 2021 , inclusive (the "Class Period"), of the important December 22, 2021 lead plaintiff deadline . SO WHAT: If you purchased BioMarin securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the BioMarin class action, go to http://www.rosenlegal.com/cases-register-2185.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. Full story available on Benzinga.com

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Research analysts at William Blair raised their Q2 2022 earnings per share estimates for BioMarin Pharmaceutical in a research report issued to clients and investors on Wednesday, December 1st. William Blair analyst T. Lugo now expects that the biotechnology company will earn $0.15 per share for the quarter, up from []

AdvisorNet Financial Inc boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 11.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,774 shares of the biotechnology companys stock after buying an additional 717 shares during the quarter. AdvisorNet Financial Incs holdings in []

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Wednesday, December 1st. The shares were sold at an average price of $87.22, for a total transaction of $130,830.00. The sale was disclosed in a filing with the SEC, which can be accessed through []

Global Mucopolysaccharidosis Market Synopsis: To accomplish highest return on investment (ROI), its very essential to know about market parameters such as brand awareness, market landscape, possible future issues, industry trends and customer behaviour where Mucopolysaccharidosis Market report comes into play. Insights

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021, inclusive (the Class Period) have until December 21, 2021 to seek appointment as lead plaintiff in Berlinger v. BioMarin Pharmaceutical Inc. , No. 21-cv-08254 (N.D. Cal.). Commenced on October 22, 2021, the BioMarin class action lawsuit charges BioMarin as well as certain of its top executives with violations of the Securities Exchange Act of 1934.

- Evercore ISI 4th Annual HealthCONx Conference on December 1 at 1:25pm ET

NEW YORK, Nov. 28, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the Class Period), of the important December 22, 2021 lead plaintiff deadline .

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target hoisted by Robert W. Baird from $101.00 to $112.00 in a research report report published on Tuesday morning, The Fly reports. Robert W. Baird currently has an outperform rating on the biotechnology companys stock. BMRN has been the topic of several other reports. Guggenheim raised their price target []

Manning & Napier Group LLC increased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 0.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,742,981 shares of the biotechnology companys stock after purchasing an additional 15,597 shares during the period. BioMarin Pharmaceutical makes up approximately 1.2% []

BioMarin Pharmaceutical (NASDAQ:BMRN) had its target price hoisted by JPMorgan Chase & Co. from $129.00 to $135.00 in a research note released on Monday morning, The Fly reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology companys stock. Other research analysts have also recently issued research reports about the company. Royal []